vs
阿特斯（CSIQ）与通用电气医疗（GEHC）财务数据对比。点击上方公司名可切换其他公司
通用电气医疗的季度营收约是阿特斯的1.3倍（$5.7B vs $4.5B），通用电气医疗净利率更高（10.3% vs 1.3%，领先9.0%）
阿特斯是全球领先的可再生能源企业，总部位于加拿大安大略省基奇纳。核心业务涵盖光伏组件制造、电池储能解决方案供应，以及大型公用事业级太阳能电站与储能项目的开发，业务布局覆盖全球主要能源市场。
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、核磁共振、女性健康筛查、X射线系统）、超声、患者护理解决方案（聚焦远程患者监测、麻醉呼吸护理、心脏病诊断、婴幼儿照护）及制药诊断业务。
CSIQ vs GEHC — 直观对比
营收规模更大
GEHC
是对方的1.3倍
$4.5B
净利率更高
GEHC
高出9.0%
1.3%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $4.5B | $5.7B |
| 净利润 | $57.6M | $588.0M |
| 毛利率 | 17.5% | 39.7% |
| 营业利润率 | 2.2% | 14.5% |
| 净利率 | 1.3% | 10.3% |
| 营收同比 | — | 7.1% |
| 净利润同比 | — | -18.4% |
| 每股收益（稀释后） | — | $1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSIQGEHC
| Q4 25 | — | $5.7B | ||
| Q3 25 | $4.5B | $5.1B | ||
| Q2 25 | $3.0B | $5.0B | ||
| Q1 25 | $1.3B | $4.8B | ||
| Q4 24 | — | $5.3B | ||
| Q3 24 | $5.9B | $4.9B | ||
| Q2 24 | $4.1B | $4.8B | ||
| Q1 24 | — | $4.7B |
净利润CSIQGEHC
| Q4 25 | — | $588.0M | ||
| Q3 25 | $57.6M | $446.0M | ||
| Q2 25 | $63.6M | $486.0M | ||
| Q1 25 | $36.2M | $564.0M | ||
| Q4 24 | — | $721.0M | ||
| Q3 24 | $366.8M | $470.0M | ||
| Q2 24 | $304.4M | $428.0M | ||
| Q1 24 | — | $374.0M |
毛利率CSIQGEHC
| Q4 25 | — | 39.7% | ||
| Q3 25 | 17.5% | 38.7% | ||
| Q2 25 | 18.0% | 39.6% | ||
| Q1 25 | 19.0% | 42.1% | ||
| Q4 24 | — | 42.8% | ||
| Q3 24 | 18.0% | 41.7% | ||
| Q2 24 | 18.7% | 41.4% | ||
| Q1 24 | — | 40.9% |
营业利润率CSIQGEHC
| Q4 25 | — | 14.5% | ||
| Q3 25 | 2.2% | 12.7% | ||
| Q2 25 | 3.3% | 13.1% | ||
| Q1 25 | 3.7% | 13.2% | ||
| Q4 24 | — | 15.1% | ||
| Q3 24 | 7.7% | 13.9% | ||
| Q2 24 | 9.1% | 12.6% | ||
| Q1 24 | — | 11.6% |
净利率CSIQGEHC
| Q4 25 | — | 10.3% | ||
| Q3 25 | 1.3% | 8.7% | ||
| Q2 25 | 2.1% | 9.7% | ||
| Q1 25 | 2.7% | 11.8% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | 6.2% | 9.7% | ||
| Q2 24 | 7.5% | 8.8% | ||
| Q1 24 | — | 8.0% |
每股收益（稀释后）CSIQGEHC
| Q4 25 | — | $1.28 | ||
| Q3 25 | — | $0.98 | ||
| Q2 25 | — | $1.06 | ||
| Q1 25 | — | $1.23 | ||
| Q4 24 | — | $1.58 | ||
| Q3 24 | — | $1.02 | ||
| Q2 24 | — | $0.93 | ||
| Q1 24 | — | $0.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $4.5B |
| 总债务越低越好 | — | $10.0B |
| 股东权益账面价值 | $3.9B | $10.4B |
| 总资产 | $13.5B | $36.9B |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资CSIQGEHC
| Q4 25 | — | $4.5B | ||
| Q3 25 | $1.7B | $4.0B | ||
| Q2 25 | $1.7B | $3.7B | ||
| Q1 25 | $1.7B | $2.5B | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | $1.9B | $3.5B | ||
| Q2 24 | $1.9B | $2.0B | ||
| Q1 24 | — | $2.6B |
总债务CSIQGEHC
| Q4 25 | — | $10.0B | ||
| Q3 25 | — | $10.3B | ||
| Q2 25 | — | $10.3B | ||
| Q1 25 | — | $8.8B | ||
| Q4 24 | — | $9.0B | ||
| Q3 24 | — | $10.3B | ||
| Q2 24 | — | $9.2B | ||
| Q1 24 | — | $9.3B |
股东权益CSIQGEHC
| Q4 25 | — | $10.4B | ||
| Q3 25 | $3.9B | $10.0B | ||
| Q2 25 | $3.9B | $9.7B | ||
| Q1 25 | $3.9B | $9.2B | ||
| Q4 24 | — | $8.4B | ||
| Q3 24 | $3.7B | $8.3B | ||
| Q2 24 | $3.7B | $7.8B | ||
| Q1 24 | — | $7.4B |
总资产CSIQGEHC
| Q4 25 | — | $36.9B | ||
| Q3 25 | $13.5B | $36.1B | ||
| Q2 25 | $13.5B | $35.5B | ||
| Q1 25 | $13.5B | $33.6B | ||
| Q4 24 | — | $33.1B | ||
| Q3 24 | $11.9B | $33.9B | ||
| Q2 24 | $11.9B | $31.9B | ||
| Q1 24 | — | $32.2B |
负债/权益比CSIQGEHC
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | — | 0.95× | ||
| Q4 24 | — | 1.06× | ||
| Q3 24 | — | 1.24× | ||
| Q2 24 | — | 1.18× | ||
| Q1 24 | — | 1.25× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-187.7M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 2.4% |
| 现金转化率经营现金流/净利润 | -3.26× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CSIQGEHC
| Q4 25 | — | — | ||
| Q3 25 | $-187.7M | — | ||
| Q2 25 | — | $94.0M | ||
| Q1 25 | — | $250.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-119.0M | ||
| Q1 24 | — | $419.0M |
自由现金流CSIQGEHC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $8.0M | ||
| Q1 25 | — | $98.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-183.0M | ||
| Q1 24 | — | $274.0M |
自由现金流率CSIQGEHC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.8% | ||
| Q1 24 | — | 5.9% |
资本支出强度CSIQGEHC
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | 3.1% |
现金转化率CSIQGEHC
| Q4 25 | — | — | ||
| Q3 25 | -3.26× | — | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | 0.44× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.28× | ||
| Q1 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSIQ
暂无分部数据
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
